The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results